专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2015079241A1 COMPOSITIONS 审中-公开
标题翻译：组合物
公开(公告)号：WO2015079241A1
公开(公告)日：2015-06-04
申请号：PCT/GB2014/053522
申请日：2014-11-27
申请人： GLOBALACORN LTD
发明人： MILLER, Andrew David , LOZOVAYA, Natalya , BURNASHEV, Nail , GINIATULLIN, Rashid
IPC分类号： A61K45/06 , A61K31/7084 , A61P25/08
CPC分类号： A61K31/7084 , A61K45/06 , A61K2300/00
摘要： The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use as an anticonvulsant and/or seizure suppressant, in particular in the treatment or prevention of (e.g. juvenile)epilepsy.
摘要翻译：本发明提供了用作抗惊厥抑制剂和/或止痫药的二核苷多聚磷酸酯类似物或其药学上可接受的盐，特别是用于治疗或预防（例如，少年）癫痫。

12. 发明申请

WO2013093484A1 PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS 审中-公开
标题翻译：吡啶酮和吡嗪酮衍生物作为因子XIA抑制剂
公开(公告)号：WO2013093484A1
公开(公告)日：2013-06-27
申请号：PCT/GB2012/053217
申请日：2012-12-20
申请人： ONO PHARMACEUTICAL CO., LTD. , COURTNEY, Steve , YARNOLD, Chris , FLANAGAN, Stuart , BRACE, Gareth , BARKER, John , ICHIHARA, Osamu , GADOULEAU, Elise , RICHARDSON, Anthony , KONDO, Takashi , IMAGAWA, Akira , NAKATANI, Shingo , SUZUKI, Ryo , KOUYAMA, Sho
发明人： COURTNEY, Steve , YARNOLD, Chris , FLANAGAN, Stuart , BRACE, Gareth , BARKER, John , ICHIHARA, Osamu , GADOULEAU, Elise , RICHARDSON, Anthony , KONDO, Takashi , IMAGAWA, Akira , NAKATANI, Shingo , SUZUKI, Ryo , KOUYAMA, Sho
IPC分类号： C07D401/14 , C07D471/04 , C07D487/04 , A61K31/437 , A61K31/519 , A61P9/00
CPC分类号： C07D487/04 , C07D401/14 , C07D403/14 , C07D471/04
摘要： The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.
摘要翻译：本发明提供了通式（I）的化合物，其盐和N-氧化物及其溶剂合物和前药（其中字符如说明书中所定义）。通式（I）的化合物是因子XIa的抑制剂，因此它们可用于预防和/或治疗血栓栓塞性疾病。

13. 发明申请

WO2008110824A2 DIAGNOSTIC TEST FOR AGE-RELATED MACULAR DEGENERATION (AMD) 审中-公开
标题翻译：与年龄相关的恶性肿瘤的诊断测试（AMD）
公开(公告)号：WO2008110824A2
公开(公告)日：2008-09-18
申请号：PCT/GB2008/000917
申请日：2008-03-14
申请人： DSM IP ASSETS B.V. , WRIGHT, Simon, Mark , BENDIK, Igor , SANCAK, Ozgür , SCHALCH, Wolfgang , WITTWER, Jonas
发明人： BENDIK, Igor , SANCAK, Ozgür , SCHALCH, Wolfgang , WITTWER, Jonas
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/172
摘要： A method of prevention of age-related macular degeneration (AMD) is provided where a sample is taken from an individual and the presence of a polymorphism associated with a dehydrogenase, oxygenase, acyltransferase, dismutase or a macular or retinal pigment, or an SNP as shown in Table 1 of the specification, is detected. The individual can then be provided with a substance that can prevent or treat AMD, or can mitigate or alleviate symptoms of AMD. The substance is a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual.
摘要翻译：提供了一种预防年龄相关性黄斑变性（AMD）的方法，其中取自个体的样品和与脱氢酶，加氧酶，酰基转移酶，岐化酶或黄斑或视网膜色素或SNP相关的多态性的存在或作为检测了表1中所示的规格。然后可以向个体提供可以预防或治疗AMD的物质，或者可以减轻或缓解AMD的症状。该物质是包含叶黄素和/或玉米黄质的药物和/或某些抗氧化剂（或其混合物）适合于该个体。

14. 发明申请

WO2004001021A1 PASTEURISATION PROCESS FOR MICROBIAL CELLS AND MICROBIAL OIL 审中-公开
标题翻译：微生物细胞和微生物油的固定过程
公开(公告)号：WO2004001021A1
公开(公告)日：2003-12-31
申请号：PCT/EP2003/006553
申请日：2003-06-20
申请人： DSM IP ASSETS B.V. , SCHAAP, Albert , VERKOEIJEN, Daniel
发明人： SCHAAP, Albert , VERKOEIJEN, Daniel
IPC分类号： C12N1/00
CPC分类号： A61L2/04 , A23D9/00 , A23D9/02 , A23K20/158 , A23L33/115 , A23L33/12 , A61K8/67 , A61K8/925 , A61K8/99 , A61K2800/85 , A61Q19/00 , C07C57/03 , C11B1/10 , C12N1/005 , C12P7/6427 , C12P7/6463 , C12P7/6472
摘要： An improved pasteurisation protocol for pasteurising microbial cells is disclosed. The protocol has three stages, a first heating stage, a second plateau stage at which the cells are held at a (maximum and) constant temperature, and a third cooling stage. Both the heating and the cooling stages are rapid, with the temperature of the cells passing through 40 to 80 °C in no more than 30 minutes in the heating stage. The heating rate is at least 0.5 °C/minute and during cooling is at least -0.5 °C/minute. The plateau maximum temperature is from 70 to 85 °C. By plotting the pasteurisation protocol on a time (t, minutes) versus temperature (T, °C) graph, one obtains a trapezium having an area less than 13,000 °C minute. Not only does this result in a smaller energy input (and so a reduction in costs), but a better quality (and less oxidised) oil results having a peroxide value (POV) of less than 1.5 and an anisidine value (AnV) of less than 1.0.
摘要翻译：公开了用于巴氏灭菌微生物细胞的改进的巴氏灭菌方案。该方案具有三个阶段，第一加热阶段，细胞保持在（最大和恒定）温度的第二平台阶段和第三冷却阶段。加热阶段和冷却阶段都是快速的，在加热阶段，在不超过30分钟内，电池的温度通过40至80℃。加热速度为至少0.5℃/分钟，冷却时为至少-0.5℃/分钟。平台最高温度为70〜85℃。通过在一段时间（t，分钟）与温度（T，°C）图上绘制巴氏消毒方案，可得到面积小于13,000℃分钟的梯形图。这不仅导致更小的能量输入（并且因此降低成本），而且具有小于1.5的过氧化值（POV）和较小的茴香胺值（AnV）的更好的质量（和较少氧化的）油的结果比1.0。

15. 发明申请

WO2003009701A1 ANIMAL FEED WITH LOW PUFA CONCENTRATION 审中-公开
标题翻译：具有低PUFA浓度的动物饲料
公开(公告)号：WO2003009701A1
公开(公告)日：2003-02-06
申请号：PCT/EP2002/008159
申请日：2002-07-22
申请人： DSM N.V. , KIES, Arie, Karst
发明人： KIES, Arie, Karst
IPC分类号： A23K1/16
CPC分类号： C12Y101/03004 , A23K20/10 , A23K20/158 , A23K20/189 , A23K50/70 , A23V2002/00 , A61K31/20 , C12Y113/11012 , A23V2200/10 , A23V2250/1862 , A23V2250/1882
摘要： The use of low concentrations of (a) PUFA (s) in an animal feed for monogastric and/or non-ruminant animals is disclosed to improve growth and feed conversion ratio. The concentration can be much lower than expected from the art, namely from 0.1 to 0.0001 g/kg feed, and yet still be effective. This may enable farmers to use lower concentrations of PUFA (s) in feed and hence reduce the cost of the feed. The feed may also have one or more antimicrobial enzymes present.
摘要翻译：公开了在单胃和/或非反刍动物的动物饲料中使用低浓度的（a）PUFA以改善生长和饲料转化率。浓度可以远远低于本领域的预期值，即0.1至0.0001g / kg饲料，仍然有效。这可能使农民在饲料中使用较低浓度的PUFA，从而降低饲料的成本。饲料还可以具有一种或多种存在的抗微生物酶。

16. 发明申请

WO2016198859A1 PRECISION THERAPEUTICS 审中-公开
标题翻译：精密治疗
公开(公告)号：WO2016198859A1
公开(公告)日：2016-12-15
申请号：PCT/GB2016/051690
申请日：2016-06-08
申请人： GLOBALACORN LTD. , KING'S COLLEGE LONDON
发明人： THANOU, Maria , WRIGHT, Michael James Lee , CENTELLES, Miguel , MILLER, Andrew David , GEDROYC, Wladyslaw , SPENCE, Paul
IPC分类号： A61K41/00 , A61K49/18 , A61K47/48 , A61K9/127 , A61P35/00
CPC分类号： A61K49/1812 , A61K9/0007 , A61K9/127 , A61K41/0028 , A61K41/0052 , A61K47/6911
摘要： The invention provides a pharmaceutical composition comprising (a combination of): - imaging lipid nanoparticles (imaging LNPs); and - one or more therapeutic agent(s). The one or more therapeutic agent(s) may be separate from said imaging LNPs, and/or entrapped within said imaging LNPs to form theranostic nanoparticles (TNPs). Imaging LNPs (or TNPs) may have receptor-targeting ligands. Post administration, when sufficient imaging LNPs (or TNPs) reach target sites such as cancerous lesions, then targets may become identified using clinically relevant imaging modalities such as MRI. Image-guided hyperthermia (IgFHT) applied to target sites enables imaging LNPs (or TNPs) still in the blood pool, along with (additional) therapeutic agent(s), to partition substantially into target tissues for therapy by means of hyperpermeability and retention (HPR). Confirmation of therapeutic outcomes can be followed by clinically relevant imaging modalities such as MRI.
摘要翻译：本发明提供了一种药物组合物，其包含（组合）：成像脂质纳米颗粒（成像LNPs）; 和 - 一种或多种治疗剂。所述一种或多种治疗剂可以与所述成像LNP分离，和/或包埋在所述成像LNPs内以形成纳米颗粒（TNPs）。成像LNPs（或TNP）可能具有受体靶向配体。后行管理，当足够的成像LNP（或TNP）到达目标部位如癌性病变时，则可以使用临床相关的成像方式（例如MRI）鉴定目标。应用于靶位点的图像引导热疗（IgFHT）使得仍然在血液池中的LNP（或TNP）与（附加的）治疗剂一起成像以通过高渗透性和保留性将其基本分配到靶组织进行治疗 HPR）。治疗结果的确认可以跟随临床相关的成像方式，如MRI。

17. 发明申请

WO2010067067A1 COMPOUNDS FOR TREATING CANCER 审中-公开
标题翻译：化合物治疗癌症
公开(公告)号：WO2010067067A1
公开(公告)日：2010-06-17
申请号：PCT/GB2009/002848
申请日：2009-12-08
申请人： EVOTEC AG , EAST, Stephen, Peter , WHITTAKER, Mark , ICHIHARA, Osamu , KOTEY, Adrian, Kotei , BAMFORD, Jayne, Samantha
发明人： EAST, Stephen, Peter , WHITTAKER, Mark , ICHIHARA, Osamu , KOTEY, Adrian, Kotei , BAMFORD, Jayne, Samantha
IPC分类号： C07D235/06 , C07D235/12 , C07D401/06 , C07D407/06 , C07D417/06 , A61K31/4184 , A61P35/00
CPC分类号： C07D235/06 , C07D235/12 , C07D401/06 , C07D407/06 , C07D417/06
摘要： Compounds of general formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Y are as defined herein are inhibitors of Bcl-2 and are useful for treating diseases characterised by abnormal cell growth and/or dysregulated apoptosis.
摘要翻译：通式（I）的化合物：其中R 1，R 2，R 3，R 4，R 5，R 6，X和Y如本文所定义，是Bcl-2的抑制剂，可用于治疗以异常细胞生长和/或失调凋亡为特征的疾病。

18. 发明申请

WO2008058709A1 ASSESSMENT AND IMPROVEMENT OF VISUAL PERFORMANCE 审中-公开
标题翻译：视觉性能的评估与改进
公开(公告)号：WO2008058709A1
公开(公告)日：2008-05-22
申请号：PCT/EP2007/009816
申请日：2007-11-13
申请人： DSM IP ASSETS B.V. , SCHALCH, Wolfgang , BARBUR, John, Lazar
发明人： SCHALCH, Wolfgang , BARBUR, John, Lazar
IPC分类号： A61B3/06 , A23L1/302
CPC分类号： A23L33/155 , A23L5/44 , A23L33/15 , A23V2002/00 , A61B3/12 , A23V2200/302 , A23V2250/211 , A23V2250/702 , A23V2250/708 , A23V2250/712
摘要： A novel method of assessing visual performance is provided, which can simulate the effect of pigment absorption on visual acuity and indicate macular pigment optical density (MPOD). The method can simulate the amounts of pigment in the eye and assess e.g. the response of the eye, (or the reaction of an individual) to different levels of blue light. The individual can be asked to detect a specific feature (a gap in Landolt rings) at decreasing contrast levels, the Landolt rings (and background) both being blue. This can provide an indication of the density or concentration of levels of macular pigments in an individual's eye which can help determine treatments or substances to be administered (carotenoids, such as lutein or zeaxanthin) to improve the individual's visual performance.
摘要翻译：提供了一种评估视觉表现的新方法，可以模拟颜料吸收对视力的影响，并指示黄斑色素光密度（MPOD）。该方法可以模拟眼睛中颜料的量，眼睛的反应（或个人的反应）对不同水平的蓝光。可以要求个人在对比度降低的情况下检测出特定的特征（Landolt戒指的间隙），兰德乐环（和背景）均为蓝色。这可以提供个人眼睛中黄斑色素的浓度或浓度的指示，其可以帮助确定待施用的处理或物质（类胡萝卜素，例如叶黄素或玉米黄质）以改善个体的视觉表现。

19. 发明申请

WO2004011635A1 GENES FROM PROPIONIBACTERIUM FREUDENREICHII ENCODING ENZYMES INVOLVED IN VITAMIN B12 BIOSYNTHESIS 审中-公开
标题翻译：维生素B12生物标志物中涉及到的来源于丙酸杆菌的编码基因
公开(公告)号：WO2004011635A1
公开(公告)日：2004-02-05
申请号：PCT/EP2003/008216
申请日：2003-07-25
申请人： DSM IP ASSETS B.V. , PEL, Herman, Jan , HOPPER, Sylvia
发明人： PEL, Herman, Jan , HOPPER, Sylvia
IPC分类号： C12N9/00
CPC分类号： C12N9/93 , C12N9/1085 , C12N9/1241 , C12N9/1288
摘要： Four new genes, and the enzymes that they encode, are disclosed, which are present in Propionibacterium freudenreichii , and which are involved in at least five steps in the biosynthetic pathway of vitamin B 12 . The four enzymes are: A: cobyrinic acid a, c-diamide synthase; B: a bifunctional enzyme, which is a cobinamide kinase and a cobinamide phosphate guanyl transferase; C: a cobalamin 5-phosphate synthase; and D: an adenosyl transferase. Genes encoding the four enzymes can be placed in Propionibacteria shuttle vectors and used to transform Propionibacteria hosts, in order to improve the production of vitamin B 12 or a precursor thereof on an industrial scale during fermentation.
摘要翻译：公开了四种新基因及其编码的酶，其存在于弗氏藤杆菌中，并且涉及维生素B12的生物合成途径中的至少五个步骤。四种酶是：A：豆油酸a，c-二酰胺合酶; B：双功能酶，它是一种辅酶酰胺激酶和一种胞嘧啶酰胺磷酸鸟嘌呤转移酶; C：钴胺素5-磷酸合成酶; 和D：腺苷酰基转移酶。编码四种酶的基因可以放置在丙酸杆菌穿梭载体中，并用于转化丙酸杆菌宿主，以便在发酵过程中以工业规模提高维生素B12或其前体的产生。

20. 发明申请

WO2003034816A1 PUFAS IN EGGS 审中-公开
标题翻译：蜂蜜中的PUFAS
公开(公告)号：WO2003034816A1
公开(公告)日：2003-05-01
申请号：PCT/EP2002/011749
申请日：2002-10-21
申请人： DSM N.V. , KIES, Arie, Karst , SIMONS, Petrus, Cornelis, Maria , VAN DOESUM, Johannes, Henricus
发明人： KIES, Arie, Karst , SIMONS, Petrus, Cornelis, Maria , VAN DOESUM, Johannes, Henricus
IPC分类号： A01K45/00
CPC分类号： A01K45/007
摘要： A process for improving the survival rate (post-hatching) or hatching rate of chicks from an egg is disclosed, where the polyunsaturated fatty acid (PUFA) content of the egg is increased. Such an increase can also improve growth, feed conversion ratio or the immunological status of the hatched chicks. Improvements in these parameters have been found even when increasing the PUFA content of the egg by as little as 0.01 %. The PUFA is transported across the shell of the egg, by manual injection, and the PUFA can be injected into the egg yolk, into the egg white, or both. Injection can be within 24 hours of the egg being laid. The invention therefore also provides novel eggs, where at least 10% of the arachidonic acid (ARA) inside the eggs is in triglyceride form. The invention also provides eggs that contain one or more PUFAs or lipids in the egg white, or where the egg (or yolk) has at least 120 mg of a PUFA such as ARA. These eggs may be intact, with a shell, or may be without the shell (and therefore in a raw or cooked form). Such eggs can be included into foodstuffs, such as for humans.
摘要翻译：公开了一种提高鸡蛋生存率（孵化后）或雏鸡孵化率的方法，其中鸡蛋的多不饱和脂肪酸（PUFA）含量增加。这样的增加也可以改善孵化雏鸡的生长，饲料转化率或免疫状态。即使将蛋黄的PUFA含量提高到0.01％，也已经发现了这些参数的改进。 PUFA通过手动注射运输穿过鸡蛋壳，PUFA可以注入蛋黄，蛋白或两者。注射可以在鸡蛋放置的24小时内。因此，本发明还提供了新颖的蛋，其中蛋中至少10％的花生四烯酸（ARA）是甘油三酯形式。本发明还提供在蛋清中含有一种或多种PUFA或脂质的蛋，或者蛋（或蛋黄）具有至少120mg的PUFA如ARA的蛋。这些蛋可以是完整的，有壳，或者可以没有壳（因此是生的或熟的形式）。这样的蛋可以包括在食物中，例如人类。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式